Cargando…

Relationship of TRIM5 and TRIM22 polymorphisms with liver disease and HCV clearance after antiviral therapy in HIV/HCV coinfected patients

BACKGROUND AND AIMS: TRIM5 and TRIM22 are restriction factors involved in innate immune response and exhibit anti-viral activity. Single nucleotide polymorphisms (SNPs) at TRIM5 and TRIM22 genes have shown to influence several viral infections such as human immunodeficiency virus (HIV), hepatitis B,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Medrano, Luz M., Rallón, Norma, Berenguer, Juan, Jiménez-Sousa, María A., Soriano, Vicente, Aldámiz-Echevarria, Teresa, Fernández-Rodríguez, Amanda, García, Marcial, Tejerina, Francisco, Martínez, Isidoro, Benito, José M., Resino, Salvador
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5010694/ https://www.ncbi.nlm.nih.gov/pubmed/27590274 http://dx.doi.org/10.1186/s12967-016-1005-7

Ejemplares similares

ADAR1 polymorphisms are related to severity of liver fibrosis in HIV/HCV-coinfected patients
por: Medrano, Luz M., et al.
Publicado: (2017)

TRIM25 in the Regulation of the Antiviral Innate Immunity
por: Martín-Vicente, María, et al.
Publicado: (2017)

FTO rs9939609 polymorphism is associated with metabolic disturbances and response to HCV therapy in HIV/HCV-coinfected patients
por: Pineda-Tenor, Daniel, et al.
Publicado: (2014)

Soluble Adhesion Molecules in Patients Coinfected with HIV and HCV: A Predictor of Outcome
por: Aldámiz-Echevarría, Teresa, et al.
Publicado: (2016)

Stroke in HIV-infected individuals with and without HCV coinfection in Spain in the combination antiretroviral therapy era
por: Alvaro-Meca, Alejandro, et al.
Publicado: (2017)

Liver Stiffness Hinders Normalization of Systemic Inflammation and Endothelial Activation after Hepatitis C Virus (HCV) Eradication in HIV/HCV Coinfected Patients
por: Álvarez, Beatriz, et al.
Publicado: (2020)

HCV Cure With Direct-Acting Antivirals Improves Liver and Immunological Markers in HIV/HCV-Coinfected Patients
por: Brochado-Kith, Óscar, et al.
Publicado: (2021)

European mitochondrial haplogroups predict liver-related outcomes in patients coinfected with HIV and HCV: a retrospective study
por: Aldámiz-Echevarría, Teresa, et al.
Publicado: (2019)

HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients
por: Brochado, Óscar, et al.
Publicado: (2021)

Mx1, OAS1 and OAS2 polymorphisms are associated with the severity of liver disease in HIV/HCV-coinfected patients: A cross-sectional study
por: García-Álvarez, Mónica, et al.
Publicado: (2017)

Association between IL7R polymorphisms and severe liver disease in HIV/HCV coinfected patients: a cross-sectional study
por: Guzmán-Fulgencio, María, et al.
Publicado: (2015)

Telomere Length Increase in HIV/HCV-Coinfected Patients with Cirrhosis after HCV Eradication with Direct-Acting Antivirals (†)
por: Molina-Carrión, Silvia, et al.
Publicado: (2020)

Prognostic value of liver stiffness in HIV/HCV-Coinfected patients with decompensated cirrhosis
por: Pérez-Latorre, Leire, et al.
Publicado: (2018)

HCV coinfection contributes to HIV pathogenesis by increasing immune exhaustion in CD8 T-cells
por: Rallón, Norma, et al.
Publicado: (2017)

Successful HCV Therapy Reduces Liver Disease Severity and Inflammation Biomarkers in HIV/HCV-Coinfected Patients With Advanced Cirrhosis: A Cohort Study
por: Medrano, Luz Maria, et al.
Publicado: (2021)

HIV-reservoir size is not affected either by HCV coinfection or by direct acting antivirals (DAAs) therapy
por: Álvarez, Beatriz, et al.
Publicado: (2022)

Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR
por: Vigón, Lorena, et al.
Publicado: (2019)

No impact of IL28B polymorphisms on liver enzymes in patients coinfected with HIV and HCV
por: Fernández-Montero, JV, et al.
Publicado: (2010)

Dysregulation of the Immune System in HIV/HCV-Coinfected Patients According to Liver Stiffness Status
por: Garcia-Broncano, Pilar, et al.
Publicado: (2018)

PPARγ2 Pro12Ala polymorphism was associated with favorable cardiometabolic risk profile in HIV/HCV coinfected patients: a cross-sectional study
por: García-Broncano, Pilar, et al.
Publicado: (2014)

All‐oral direct‐acting antiviral therapy against hepatitis C virus (HCV) in human immunodeficiency virus/HCV–coinfected subjects in real‐world practice: Madrid coinfection registry findings
por: Berenguer, Juan, et al.
Publicado: (2018)

Pangenotypic and Genotype-Specific Antivirals in the Treatment of HCV Genotype 4 Infected Patients with HCV Monoinfection and HIV/HCV Coinfection
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2022)

HCV-coinfection is related to an increased HIV-1 reservoir size in cART-treated HIV patients: a cross-sectional study
por: López-Huertas, Maria Rosa, et al.
Publicado: (2019)

Prevalence of hepatitis E infection in HIV/HCV-coinfected patients in Spain (2012–2014)
por: Vázquez-Morón, Sonia, et al.
Publicado: (2019)

TRIM26 is a critical host factor for HCV replication and contributes to host tropism
por: Liang, Yisha, et al.
Publicado: (2021)

TRIM22. A Multitasking Antiviral Factor
por: Pagani, Isabel, et al.
Publicado: (2021)

Pharmacologic management of HCV treatment in patients with HCV monoinfection vs. HIV/HCV coinfection: Does coinfection really matter?
por: Zuckerman, Autumn D., et al.
Publicado: (2019)

HTLV-1 infection modulates the immune response in HIV-HCV coinfected patients and may increase spontaneous HCV clearance
por: Bahia, Fabianna, et al.
Publicado: (2014)

miR-215 Enhances HCV Replication by Targeting TRIM22 and Inactivating NF-κB Signaling
por: Tian, Hui, et al.
Publicado: (2018)

Baseline Plasma Metabotype Correlates With Direct-Acting Antiviral Therapy Nonresponse for HCV in HIV–HCV Coinfected Patients
por: Tripathi, Gaurav, et al.
Publicado: (2022)

Effect of Direct Antiviral Therapy Against HCV on CD4+ T Cell Count in Patients with HIV-HCV Coinfection
por: Pinchera, Biagio, et al.
Publicado: (2023)

Enhanced host immune responses in presence of HCV facilitate HBV clearance in coinfection
por: Liu, Shuhui, et al.
Publicado: (2022)

Managing HCV/HIV coinfection
por: Danish, Fazal A., et al.
Publicado: (2009)

Comparison of methods and characterization of small RNAs from plasma extracellular vesicles of HIV/HCV coinfected patients
por: Martínez-González, Elena, et al.
Publicado: (2020)

356. HIV-HCV Coinfection: An Investigation of CD4 T-Cell Reconstitution after HCV Direct-Acting Antiviral Treatment
por: Michienzi, Sarah M, et al.
Publicado: (2019)

T-cell Activation Is Correlated With Monocyte Activation in HCV/HIV Coinfection and Declines During HCV Direct-Acting Antiviral Therapy
por: Auma, Ann W N, et al.
Publicado: (2021)

TRIM22: A Diverse and Dynamic Antiviral Protein
por: Hattlmann, Clayton J., et al.
Publicado: (2012)

Liver Enzyme Alterations in HCV-Monoinfected and HCV/HIV-Coinfected Patients
por: Langohr, Klaus, et al.
Publicado: (2008)

Impact of HCV viremia on HBV biomarkers in patients coinfected with HBV and HCV
por: Tseng, Chih-Wei, et al.
Publicado: (2022)

The Burgeoning HIV/HCV Syndemic in the Urban Northeast: HCV, HIV, and HIV/HCV Coinfection in an Urban Setting
por: Morano, Jamie P., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_2to8lilk9dl3vlf3pbu82r0ag4